NASDAQ:ZY Zymergen (ZY) Stock Price, News & Analysis → A.I. is a Tidal Wave - Here’s What to Buy (From Chaikin Analytics) (Ad) Free ZY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.43▼$2.4350-Day Range$2.35▼$3.1452-Week Range$1.10▼$12.42Volume85 shsAverage Volume1.23 million shsMarket Capitalization$253.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zymergen alerts: Email Address Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Zymergen Stock (NASDAQ:ZY)Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.Read More Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. ZY Stock News HeadlinesMay 10, 2024 | seekingalpha.comGinkgo Bioworks: Broken NarrativeMay 7, 2024 | finance.yahoo.comSynthetic Biology Market To Reach USD 57.1 Billion By 2032, Report By DataHorizzon ResearchMay 11, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...April 10, 2024 | finance.yahoo.comMethod Communications Introduces New Leadership Structure to Accelerate MomentumMarch 21, 2024 | tmcnet.comMolecular Robotics Market Share Analysis, Industry Trends & Statistics and 10 Year Growth Forecasts 2019-2029March 13, 2024 | msn.comGM Appoints Former Tesla and Google Executive to Succeed Retiring Head of ManufacturingMarch 13, 2024 | marketwatch.comGM Taps Former Tesla Gigafactory Head To Lead ManufacturingMarch 1, 2024 | finance.yahoo.comQ4 2023 Ginkgo Bioworks Holdings Inc Earnings CallMay 11, 2024 | TradeSmith (Ad)The A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...February 13, 2024 | finance.yahoo.comMATTERWORKS ANNOUNCES BOARD UPDATESJanuary 19, 2024 | bizjournals.comSmartLabs gets $48M investment; CEO says 'we’re not done'January 11, 2024 | finance.yahoo.comSmartLabs Announces Biopharma Veteran Brian Taylor as New Interim CEONovember 8, 2023 | finance.yahoo.comGinkgo Bioworks Holdings Inc (DNA) Reports Q3 2023 Financial ResultsNovember 8, 2023 | msn.comTech and biotech firms slash hundreds of Bay Area jobs as layoffs widenNovember 7, 2023 | msn.comGinkgo Bioworks Holdings Q3 2023 Earnings PreviewOctober 24, 2023 | msn.comGingko Bioworks, Penn State partner on wildlife biothreat researchOctober 4, 2023 | msn.comGinkgo Bioworks and Zymergen: A tale of two IPOs ends in bankruptcyOctober 4, 2023 | markets.businessinsider.comAnalyst Cautions on Ginkgo Bioworks’ Financial Prospects Despite Promising Collaborations and Sector PositionSeptember 27, 2023 | benzinga.comAccelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A CommitmentsSeptember 19, 2023 | finance.yahoo.comTarsadia Strengthens Venture, Growth & Private Investing Practice with New Sector HeadsSeptember 14, 2023 | sg.news.yahoo.comAl Gore and Lila Preston ask the tough questions in their firm's new climate reportSeptember 13, 2023 | ca.style.yahoo.comAl Gore and Lila Preston question everything in their firm's new climate reportSeptember 13, 2023 | techcrunch.comAl Gore and Lila Preston ask the tough questions in their firm’s new climate reportAugust 22, 2023 | finance.yahoo.comMycoWorks Welcomes Three Executives to Leadership TeamAugust 22, 2023 | venturebeat.comCascade Biocatalysts Secures $2.6 M to Scale Enzymes for BiomanufacturingMay 23, 2023 | bizjournals.comLife sciences incubator in Vacaville looks to attract, retain hub's biotechsMay 17, 2023 | marketwatch.comNano Robots Market Reports, Scope, Methodology, Timelines And Challenges Forecast Till 2030See More Headlines Receive ZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymergen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBasic Materials Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:ZY CUSIPN/A CIK1645842 Webwww.zymergen.com Phone415-801-8073FaxN/AEmployees502Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-361,790,000.00 Net Margins-2,508.94% Pretax Margin-2,508.42% Return on Equity-93.37% Return on Assets-61.14% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.47 Sales & Book Value Annual Sales$16.74 million Price / Sales15.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.99 per share Price / Book0.61Miscellaneous Outstanding Shares104,355,000Free Float92,145,000Market Cap$253.58 million OptionableNot Optionable Beta1.69 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Enakshi Singh (Age 44)Chief Financial Officer Comp: $390.3kMr. Dmitriy RyaboyChief Technology OfficerMike DulinDirector of CommunicationsMr. Lincoln GermainChief Commercial OfficerMr. Subodh S. DeshmukhChief Devel. OfficerMr. Devin ScannellSr. VP of Drug DiscoveryMr. Duane Valz J.D.Sec.Ms. Mina Kim (Age 48)Corp. Sec. More ExecutivesKey CompetitorsPiedmont LithiumNASDAQ:PLLRayonier Advanced MaterialsNYSE:RYAMDakota GoldNYSE:DCIntrepid PotashNYSE:IPITredegarNYSE:TGView All Competitors ZY Stock Analysis - Frequently Asked Questions What is Joshua Hoffman's approval rating as Zymergen's CEO? 64 employees have rated Zymergen Chief Executive Officer Joshua Hoffman on Glassdoor.com. Joshua Hoffman has an approval rating of 62% among the company's employees. This puts Joshua Hoffman in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 58.0% of employees surveyed would recommend working at Zymergen to a friend. When did Zymergen IPO? Zymergen (ZY) raised $401 million in an initial public offering on Thursday, April 22nd 2021. The company issued 13,600,000 shares at $28.00-$31.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen, UBS Investment Bank and Lazard served as the underwriters for the IPO. This page (NASDAQ:ZY) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymergen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.